11/13
12:45 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
11/13
12:45 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
11/4
08:19 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
10/31
07:59 am
oric
Rating for ORIC
Low
Report
Rating for ORIC
10/31
07:59 am
oric
Rating for ORIC
Low
Report
Rating for ORIC
10/31
07:36 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $20.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $20.00 price target on the stock.
10/31
06:30 am
oric
Oric Pharmaceuticals initiated with bullish view at Wells Fargo
Low
Report
Oric Pharmaceuticals initiated with bullish view at Wells Fargo
10/31
06:30 am
oric
Oric Pharmaceuticals initiated with bullish view at Wells Fargo
Low
Report
Oric Pharmaceuticals initiated with bullish view at Wells Fargo
9/23
08:53 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/23
08:36 am
oric
Rating for ORIC
Medium
Report
Rating for ORIC
9/18
02:07 pm
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
9/10
09:12 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
9/10
09:12 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
9/10
08:56 am
oric
Rating for ORIC
Medium
Report
Rating for ORIC
9/10
08:56 am
oric
Rating for ORIC
Medium
Report
Rating for ORIC
9/9
02:14 pm
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/9
01:18 pm
oric
Rating for ORIC
Low
Report
Rating for ORIC
9/6
11:27 am
oric
Rating for ORIC
Medium
Report
Rating for ORIC
9/6
07:56 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $20.00 price target on the stock.
9/6
07:56 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $20.00 price target on the stock.